Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest

Key Points

• Short interest in Radiopharm Theranostics surged 197.3% in March to 95,200 shares as of March 31, equal to about 0.8% of shares sold short and a very low short‑interest ratio of 0.2 days due to high average daily volume.
• Several institutions opened or increased positions—Marex, Jane Street, Virtu and HSBC initiated stakes (HSBC ~ $1.01M) and PNC doubled its holding—signaling renewed institutional interest.
• The company reported a quarterly loss (EPS -$1.58) on $0.46M revenue, its stock trades near $4.66 (52‑week range $3.62–$16.25), and analysts are mixed but show a consensus price target of $14 with an average rating of "Moderate Buy."

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 95,200 shares, a growth of 197.3% from the March 15th total of 32,019 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 580,439 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Radiopharm Theranostics

Several hedge funds and other institutional investors have recently bought and sold shares of RADX. Marex Group plc purchased a new position in Radiopharm Theranostics during the fourth quarter worth approximately $54,000. Jane Street Group LLC purchased a new position in Radiopharm Theranostics during the fourth quarter worth approximately $76,000. Virtu Financial LLC purchased a new position in Radiopharm Theranostics during the fourth quarter worth approximately $76,000. PNC Financial Services Group Inc. boosted its position in Radiopharm Theranostics by 100.0% during the third quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company's stock worth $88,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Radiopharm Theranostics during the fourth quarter worth approximately $1,007,000.

Radiopharm Theranostics Stock Down 0.2%

Radiopharm Theranostics stock traded down $0.01 during midday trading on Friday, hitting $4.66. 41,233 shares of the company were exchanged, compared to its average volume of 404,926. Radiopharm Theranostics has a fifty-two week low of $3.62 and a fifty-two week high of $16.25. The business has a fifty day simple moving average of $4.76 and a two-hundred day simple moving average of $5.14.

Radiopharm Theranostics (NASDAQ:RADX - Get Free Report) last posted its earnings results on Wednesday, January 28th. The company reported ($1.58) EPS for the quarter. The company had revenue of $0.46 million during the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered Radiopharm Theranostics to a "strong sell" rating in a report on Friday, January 23rd. B. Riley Financial reissued a "buy" rating and issued a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company's research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.